Setting the Stage to Find Drugs Against SARSNovember 20, 2006UPTON, NY-Scientists at the U.S. Department of Energy's Brookhaven National Laboratory have set the stage for the rapid identification of compounds to fight against severe acquired respiratory syndrome (SARS), the atypical pneumonia responsible for about 800 deaths worldwide since first recognized in late 2002. Researchers from Brookhaven's biology department and the National Synchrotron Light Source (NSLS) characterized a component of the virus that will be the target of new anti-SARS virus drugs. The results were published online by Biochemistry on November 17, 2006. "Although vaccines against viruses are very effective, vaccines for viruses that mutate rapidly - such as the viruses that cause SARS, AIDS, and bird flu - are much more difficult to obtain," said Brookhaven biologist Walter Mangel, the lead author of the paper. "Even if a vaccine is available, antiviral agents are important in stopping the spread of highly infectious viruses. If antiviral agents for SARS had been available, they could have been used to contain the outbreak to the initial site of the infection." The researchers studied the SARS main proteinase, an enzyme used by the virus during infection to cut newly made viral proteins into gene-sized, functioning pieces. If the proteinase is prevented from working, the virus infection is aborted. Previous studies have revealed that the proteinase is inactive when in the form of single molecules. But once two of those molecules bind together to make what is called a dimer, the enzyme becomes active and is able to play its role in SARS virus reproduction. The challenge for researchers, and the focus of the Brookhaven study, was to determine the concentration at which individual proteinase molecules form active dimers. Knowing this concentration, for which estimates at other laboratories have varied greatly, would allow researchers to search for anti-SARS drugs more efficiently by ensuring that the proteinase used in tests is initially in its active form. Using three different scientific techniques, including x-ray scattering at the NSLS, the Brookhaven researchers obtained almost identical values for this concentration. Now that this crucial value has been narrowed down to a precise range, researchers can focus on finding compounds that bind to the active form of the enzyme. "Targets for antiviral drugs must be carefully chosen such that binding to it prevents the virus from reproducing," Mangel said. "Viral proteinases are excellent targets for antiviral drugs. One reason so many people are surviving the AIDS epidemic is the effectiveness of drugs targeted to the proteinase of human immunodeficiency virus (HIV)." One way to obtain compounds that bind to a proteinase is via high-throughput screening. Chemical libraries containing tens of thousands of small compounds are available that can be searched for effective drugs against various diseases. Small amounts of a target, e.g., an active viral proteinase, are placed in tiny wells in a plate, and a different compound from the library is added to each well. To determine whether a compound binds to and inhibits the proteinase, an additional molecule is added that changes color in the presence of an active proteinase. Wells that don't show a color change therefore contain compounds that inhibit the proteinase, and could be effective antiviral agents. Earlier this year, Mangel's research group published a procedure on the synthesis of a new compound that changes color in the presence of the active form of the SARS main proteinase. However, for this screening process to work, the SARS proteinase inserted into the wells has to be active to begin with. Knowing the concentration range for dimer formation will therefore help researchers in their search for a compound to stop the virus. "Now that the stage is set, high-throughput screening can begin," Mangel said. "Hopefully, it will yield an antiviral agent that can be stockpiled before a virulent strain of the virus reappears." This research was supported by the Office of Basic Energy Sciences within the U.S. Department of Energy and the National Institutes of Health. Brookhaven National Laboratory |
|||||||||||||||||||||
| Related SARS Current Events and SARS News Articles 2-pronged protein attack could be source of SARS virulence Ever since the previously unknown SARS virus emerged from southern China in 2003, University of Texas Medical Branch at Galveston virologists have focused on finding the source of the pathogen's virulence - its ability to cause disease. Will genomics help prevent the next pandemic? This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease. Paradigm shift needed to combat drug resistance When people travel, bacteria and other infectious agents travel with them. As about a billion people cross international borders each year, many more billions of the bugs come along for the ride. What are coral reef services worth? $130,000 to $1.2 million per hectare, per year: experts Experts concluding the global DIVERSITAS biodiversity conference today in Cape Town described preliminary research revealing jaw-dropping dollar values of the "ecosystem services" of biomes like forests and coral reefs - including food, pollution treatment and climate regulation. Should noninvasive ventilation be considered a high-risk procedure during an epidemic? Contrary to current policies recommending that non-invasive ventilation be avoided during an infectious outbreak, the author of a commentary in CMAJ (Canadian Medical Association Journal) argues that it should be used expeditiously in this setting. World will miss 2010 target to stem biodiversity loss, experts say The world will miss its agreed target to stem biodiversity loss by next year, according to experts convening in Cape Town for a landmark conference devoted to biodiversity science. Surgical masks and N95 respirators provide similar protection against influenza A McMaster University study has found that surgical masks appear to be as good as N95 respirators in protecting health-care workers against influenza. Medical ethics experts identify, address key issues in H1N1 pandemic The anticipated onset of a second wave of the H1N1 influenza pandemic could present a host of thorny medical ethics issues best considered well in advance, according to the University of Toronto Joint Centre for Bioethics, which today released nine papers for public discussion. Swine Flu Could Wreak More Havoc on U.S. Economy, Says UAB Economist H1N1 influenza could slow growth in key industries and stall already-weak GDP growth in the third and fourth quarters of 2009, says a health economist in the University of Alabama at Birmingham (UAB) School of Business. Public attitudes to new technology: Lessons for regulators New technologies may change our lives for the better, but sometimes they have risks. Communicating those benefits and risks to the public, and developing regulations to deal with them, can be difficult - particularly if there's already public opposition to the technology. More SARS Current Events and SARS News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||